"2. Methods
In this study, nine patients were introduced from four referral centers for neuromuscular disorders in Iran between April 8 and June 20, 2021. Four patients had received Sputnik V, two patients had received the Sinopharm, and one patient had received the AstraZeneca [Covid] vaccine. According to clinical examination, laboratory tests, including CSF analysis and electrodiagnostic (EDX) study, all patients were diagnosed with GBS [Guillain-Barre Syndrome]...
5. Conclusion
...GBS [occurred] after receiving the first dose of vector-based and inactivated COVID-19 vaccine 4–37 days after vaccination. The link between the COVID-19 vaccine and GBS is not well understood, but possible mechanisms such as epitopes cross-reaction have been implicated..."